Novonesis Delivered Strong Start To The Year With 7% Organic Sales Growth In Q1

(MENAFN- GlobeNewsWire - Nasdaq) COPENHAGEN, Denmark – May 5, 2026. In the first quarter of 2026, Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.8%.

Ester Baiget, President & CEO:

Highlights of our Q1 2026 results:

. Strong broad-based organic sales growth of 7% including ~1.5 pp effect from exiting certain countries. Price and revenue synergies contributed ~1 pp each.
. Food & Health Biosolutions grew 9% organically including ~3 pp effect from exiting certain countries; Planetary Health Biosolutions grew 5% organically.
. Developed Markets grew 8% organically and Emerging Markets 4% including ~3 pp effect from exiting certain countries.
. Adjusted EBITDA margin at 37.8% including a significant year-on-year currency headwind.
. Adjusted net profit excl. PPA increased 8%.
. NIBD/EBITDA at 2.0x, and free cash flow before acquisitions increased 9% to EUR 74 million. CAPEX ratio at 8.3%.
. Successful inaugural bond issuance of EUR 1.7 billion completed to refinance a bridge loan facility.
. Acquisition of a production facility in Thailand to support growth journey.
. 2026 outlook confirmed: Organic sales growth is expected to be in the range of 5-7% which includes a close to 1 pp effect from exiting certain countries. Adjusted EBITDA margin expected to be between 37-38%.
Here is the link to the investor call on Novonesis Q1 2026 results:

Get in touch
Media relations
Benjamin Hjorth
Senior Press Manager
...
+45 30 77 13 12
Tobias Bjorklund
Head of Investor Relations
...

MENAFN05052026004107003653ID1111068518